Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Everest

Everest makes mRNA vaccines

Everest Medicines drives growth with AI-powered mRNA pipeline

The company said the U.S. FDA has cleared the IND application for its self-developed EVM14, a tumor-associated antigen vaccine Key Takeaways: The FDA has cleared Everest Medicine’s EVM14 cancer vaccine…
March 25, 2025
1952.HK

BRIEF: Everest unveils positive results for kidney drug EVER001 in Phase 1b/2a trial

Everest Medicines (1952.HK) announced on Wednesday that its EVER001, a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor for treatment of primary membranous nephropathy (pMN), showed positive results in its…
December 5, 2024
1952.HK
Everest's nefecon included on national drug list

Everest gets boost from core product Nefecon’s inclusion in China’s national health plan

Nefecon’s addition to China’s NRDL will increase its reach and market share, lifting the drug’s competitive advantage and brand recognition Key Takeaways: Everest Medicines’ Nefecon kidney drug was approved for…
December 2, 2024
1952.HK
Everest Medicines eyes cash break even

Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound

The innovative drug maker’s stock jumped more than 18% in a single day on high hopes for inclusion of its blockbuster new drug, Nefecon, in China’s national reimbursement drug list…
October 24, 2024
1952.HK

Everest Joins Race to Make mRNA Covid Vaccines for China

Company’s move comes as Beijing shows growing signs of approving the new type of high-tech vaccination Key takeaways: Everest will pay up to $150 million or more to potentially bring…
September 21, 2021

Recent Articles

Everest makes mRNA vaccines
March 25, 2025

Everest Medicines drives growth with AI-powered mRNA pipeline

1952.HK
December 5, 2024

BRIEF: Everest unveils positive results for kidney drug EVER001 in Phase 1b/2a trial

1952.HK
December 2, 2024

Everest gets boost from core product Nefecon’s inclusion in China’s national health plan

1952.HK
October 24, 2024

Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound

1952.HK
September 21, 2021

Everest Joins Race to Make mRNA Covid Vaccines for China

RELATED ARTICLES

  1. Everest's nefecon included on national drug list
    December 2, 2024
    Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
  2. April 3, 2025
    Dispute over Covid vaccines casts doubt on Clover Bio recovery
    2197.HK
  3. January 20, 2025
    Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
    ZYBT.US
  4. January 16, 2025
    WuXi Biologics sells vaccine plant as new U.S. law looms
    2269.HK
  5. March 20, 2025
    A blockbuster cancer drug? TYK’s claims go under the microscope
    2410.HK
  6. January 9, 2025
    Cancer drug maker Genfleet joins Hong Kong IPO influx
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.